Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

被引：9
|
作者：
Strugov, Vladimir [1 ]
Stadnik, Elena [1 ,2 ]
Virts, Yulia [1 ]
Andreeva, Tatyana [1 ]
Zaritskey, Andrey [1 ,2 ]
机构：
[1] Almazov Natl Med Res Ctr, Inst Hematol, Akkuratova St 2, St Petersburg 197341, Russia
[2] Pavlov First St Petersburg State Med Univ, Div Hematol, St Petersburg 197022, Russia
来源：
ANNALS OF HEMATOLOGY | 2018年 / 97卷 / 11期
关键词：
CLL; Chronic lymphocytic leukemia; CIRS-G; Comorbidities; FCR; MYELOID-LEUKEMIA; SURVIVAL; TRIAL; CELL; FLUDARABINE; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; PROGRESSION; EXPRESSION; GUIDELINES;
D O I：
10.1007/s00277-018-3409-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CLL is an aging-associated neoplasm with median age at diagnosis >65years. Little is known about safety and efficacy of FC/FCR regimens in elderly CLL patients with multiple comorbidities. We retrospectively revised medical records of 90 patients treated with FC/FCR regimens in our clinic. Data on demographic and biological characteristics, comorbidities, response to therapy, and treatment-associated adverse events were analyzed. Compared to FC, FCR yielded higher rates of OR (93.6 vs. 81.4%, p=.109) and CR (72.3 vs. 46.5%, p=.018). This translated in longer EFS (median 52 vs. 19months, p=<.001) and OS (median 89 vs. 45months, p=.001). Elderly patients (65 years) had more comorbidities and higher median CIRS-G score (7 vs. 4, p<.001). However, no association was found between CIRS-G score and survival. Decreased renal function was associated with dismal prognosis in patients treated with FCR.
引用
收藏
页码：2153 / 2161
页数：9
相关论文
共 50 条
  • [41] Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
    Kater, Arnon P.
    van Oers, Marinus H. J.
    van Norden, Yvette
    van der Straten, Lina
    Driessen, Julia
    Posthuma, Ward F. M.
    Schipperus, Martin
    Chamuleau, Martine E. D.
    Nijland, Marcel
    Doorduijn, Jeanette K.
    Van Gelder, Michel
    Hoogendoorn, Mels
    De Croon, Francien
    Wittebol, Shulamiet
    Kerst, J. Martijn
    Marijt, Erik W. A.
    Raymakers, Reinier A. P.
    Schaafsma, Martijn R.
    Dobber, Johan A.
    Kersting, Sabina
    Levin, Mark-David
    HAEMATOLOGICA, 2019, 104 (01) : 147 - 154
  • [42] Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis
    Muhammad Hossein Ashoub
    Amirreza Naseri
    Parisa Mohammadi
    Masoud Mohammadi
    Annals of Hematology, 2023, 102 : 1301 - 1306
  • [43] Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study
    Bravo, Julio
    Tello, Patricia Baltasar
    Garcia, Esther Gonzalez
    Herranz, Eduardo Rios
    Payer, Angel Ramirez
    Castera, Maria Jose Terol
    Champ, Diana
    Perez, Angeles Medina
    Gironella, Mercedes
    Zarzoso, Miguel Fernandez
    Fores, Rafael
    Delgado, Julio
    Garcia-Marco, Jose A.
    GABRIELL Study Group Investigators
    LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 913 - 926
  • [44] Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
    Tombak, Anil
    Tanrikulu, Funda Pepedil
    Durusoy, Salih Sertac
    Dincyurek, Huseyin Derya
    Kaya, Emin
    Umit, Elif Gulsum
    Yavasoglu, Irfan
    Mehtap, Ozgur
    Deveci, Burak
    Ozcan, Mehmet Ali
    Terzi, Hatice
    Okay, Mufide
    Sayinalp, Nilgun
    Yilmaz, Mehmet
    Okan, Vahap
    Kizikli, Alperen
    Ozcan, Omer
    Cetin, Guven
    Demircioglu, Sinan
    Aydogdu, Ismet
    Saydam, Guray
    Davulcu, Eren Arslan
    Ilhan, Gul
    Ucar, Mehmet Ali
    Ozet, Gulsum
    Akpinar, Seval
    Turgut, Burhan
    Berber, Ilhami
    Kurtoglu, Erdal
    Sonmez, Mehmet
    Batur, Derya Selim
    Yildirim, Rahsan
    Ozkocamaz, Vildan
    Gunes, Ahmet Kursad
    Sahip, Birsen
    Ertop, Sehmus
    Akay, Olga Meltem
    Basturk, Abdulkadir
    Dogu, Mehmet Hilmi
    Akdeniz, Aydan
    Unal, Ali
    Seyhanli, Ahmet
    Gurkan, Emel
    Cekdemir, Demet
    Ferhanoglu, Burhan
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 273 - 285
  • [45] Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints
    Molica, Stefano
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (07) : 279 - 285
  • [46] Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
    Lin, Katherine I.
    Tam, Constantine S.
    Keating, Michael J.
    Wierda, William G.
    O'Brien, Susan
    Lerner, Susan
    Coombes, Kevin R.
    Schlette, Ellen
    Ferrajoli, Alessandra
    Barron, Lynn L.
    Kipps, Thomas J.
    Rassenti, Laura
    Faderl, Stefan
    Kantarjian, Hagop
    Abruzzo, Lynne V.
    BLOOD, 2009, 113 (14) : 3168 - 3171
  • [47] The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience
    Sevinc, Mustafa
    Karabulut, Aydin
    Eskazan, Ahmet Emre
    Tatonyan, Suzin Catal
    Ozbek, Ugur
    Soysal, Teoman
    LABORATORY MEDICINE, 2020, 51 (03) : 259 - 264
  • [48] Vaccination efficacy in patients with chronic lymphocytic leukemia
    Wang, Kevin Y.
    Shah, Pratik
    Skavla, Brandon
    Fayaaz, Fatima
    Chi, Jeffrey
    Rhodes, Joanna M.
    LEUKEMIA & LYMPHOMA, 2023, 64 (01) : 42 - 56
  • [49] Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty
    Hilal, Talal
    Betcher, Jeffrey A.
    Leis, Jose F.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (04) : 237 - 243
  • [50] Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations
    Reda, G.
    Orofino, N.
    Cassin, R.
    Sciume, M.
    Fattizzo, B.
    Cortelezzi, A.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 865 - 873
12345